A phase 3 study to evaluate efficacy and safety of HCP1401

A randomized, double-blind, multicenter, phase 3 study to evaluate efficacy and safety of HCP1401 for stage 2 hypertension patients not controlled by HCP0605

Inclusion Criteria:

• Hypertension patient who satisfied below condition at Visit 1.

  • patient who takes antihypertensive drug

    • 140mmHg <= sitSBP <= 200mmHg

  • patient who doesn't take antihypertensive drug

    • 160mmHg <= sitSBP <= 200mmHg
    • 140mmHg <= sitSBP <= 200mmHg at Visit 2

Exclusion Criteria:

• Patient who have received 4 or more antihypertensive drug
• Patient with 20mmHg of difference in sitSBP or 10mmHg of difference in sitDBP between 3 times of BP measuring at Visit 1
• Patient with sitDBP >= 120mmHg at Visit 2
• Patient with secondary hypertension